The Medicines Patent Pool (MPP) has signed agreements with ten patent holders for 13 HIV antiretrovirals, one HIV technology platform, a tuberculosis treatment and three hepatitis C direct-acting antivirals. 22 generic manufacturers and product developers have now signed MPP sublicensing agreements.
Generic competition is making a difference in fostering lower prices and improving treatment coverage. Generic partners have distributed 38.75 million patient-years of HIV and hepatitis C products, saving international procurers USD 1.66 billion (January 2012-June 2020).
Slide decks highlighting progress of MPP’s generic partners in developing, manufacturing and supplying MPP-licensed medicines, are available for:
- all MPP’s sublicensees – updated twice a year, linked to the KPMG report on MPP’s impact (Last update: October 2020 – data as of June 2020)
- dolutegravir (DTG)-based regimens
- daclatasvir (DAC)-based regimens
(Last update: October 2020 – data as of June 2020)
*[WHO-PQ] Prequalification from the World Health Organization | **[USFDA] U.S. Food and Drug Administration | ***[ERP] Expert Review Panel led by the Global Fund. Temporary approval through an ERP is permitted where WHO-PQ or USFDA approval are not yet available. This does not apply to products under licences with Gilead Sciences (those licences do not accept ERP).
– Patent and licensing status: last updated on 12 October 2020;
– Product availability data from MPP sublicensees: last updated on 20 January 2021 (data as of 30 September 2020).
Last update of the interactive table: 30 September 2020 (data as of 30 June 2020)